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Abstract
Background: Much recent research effort in traumatic brain injury (TBI) has been devoted to the discovery of a reliable
biomarker correlating with severity of injury. Currently, no consensus has been reached regarding a representative marker
for traumatic brain injury. In this study, we explored the potential of epithelial/endothelial tyrosine kinase (Etk) as a novel
marker for TBI.
Methodology/Principal Findings: TBI was induced in Sprague Dawley (SD) rats by controlled cortical impact. Brain tissue
samples were analyzed by Western blot, Q-PCR, and immunofluorescence staining using various markers including glial
fibrillary acidic protein, and epithelial/endothelial tyrosine kinase (Etk). Results show increased Etk expression with increased
number and severity of impacts. Expression increased 2.36 to 7-fold relative to trauma severity. Significant upregulation of
Etk appeared at 1 hour after injury. The expression level of Etk was inversely correlated with distance from injury site. Etk
and trauma/inflammation related markers increased post-TBI, while other tyrosine kinases did not.
Conclusion/Significance: The observed correlation between Etk level and the number of impacts, the severity of impact,
and the time course after impact, as well as its inverse correlation with distance away from injury site, support the potential
of Etk as a possible indicator of trauma severity.
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Introduction
The discovery of a reliable biomarker correlating with
severity of injury has been the focus of much of the recent
research effort in traumatic brain injury (TBI). An ideal
biomarker would exhibit a rapid change signifying sensitivity
to disease, tissue specificity, and diagnostic value for the disease.
For TBI, the biomarker would have added value if it could also
be used to predict neurological condition and serve as a
surrogate endpoint for evaluation of treatment. Currently, no
consensus has been reached regarding a representative marker
for traumatic brain injury [1]. Previous studies show significant
post-TBI increases of S-100, glial fibrillary acidic protein
(GFAP), neuron-specific enolase (NSE), neurofilament polypep-
tides, and tau. However, while these markers demonstrate
potential as indicators of TBI [2,3,4], the study results showed a
lack of correlation of these markers with clinical trauma severity
[5,6,7,8] and suggested limitations in the discriminative powerof
some of these biomarkers alone [9].
Although the general pathophysiology of TBI is still unclear,
recent research has revealed several possible mechanisms under-
lying TBI [1,10]. While some studies suggest the disruption of the
blood-brain barrier as a main cause of secondary injury [11],
much of the literature focuses on mechanisms involving lipid
peroxidation and the activation of calpain by the increase of
intracellular calcium [12,13,14,15]. Calpain is also known to
activate Hsp70 and lysosomal release of cathepsin which results in
axonal beading and diffuse axonal injury after TBI [16,17].
Many therapeutic targets involving the cascade triggered by
lipid peroxidation are currently under investigation for use in the
treatment of TBI. Therapeutic strategies suggested include the
reduction of mitochondrial free radical production [14,15,18,19]
and the scavenging of peroxynitrite-derived free radicals with
tempol and melatonin [18,20,21]. The use of estrogen, progester-
one, telmisartan and wogonin has also been suggested to limit
damage secondary to TBI [22,23,24,25]. Calpain activates many
injury pathways with its proteolytic activity on myelin basic
protein [26]and mediation of collapsin mediator proteins21, 22,
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treatment [13,14,15,27,28,29,30,31,32].
Many peptides produced by proteolytic reactions caused by
calpain activation, such as alpha-spectrin derivatives, have been
considered as markers for TBI [33]. The elevation of calpain-
derived alpha-spectrin among other markers in cerebrospinal fluid
was observed at 24 hours after TBI with peak levels not reached
until 48–96 hours [34]. As early detection of TBI severity is
desirable [34], we sought to find other factors which may underly
the initiation of injury.
A tyrosine kinase of interest is the tec kinase bone marrow
tyrosine kinase gene in chromosome X (Bmx) which is also known
as epithelial/endothelial tyrosine kinase (Etk) [35]. Most literature
thus far regard Bmx/Etk as a modulator of apoptosis and cancer
cell growth, and its cell-specific function has been characterized in
various cancer cells [36]. Studies have also shown the Bmx/Etk-
dependent pathway to be crucial in ischemic brain injury for the
recruitment of inflammatory cells and angiogenesis at the site of
injury [12,37,38]. Genetic profiling suggests that an increased
expression of Bmx/Etk induces chronic inflammation and
Figure 1. Etk is up-regulated after TBI. (A, B) Extracts of rat brains treated without impact (Normal), impacted once (impact1) or
impacted twice (impact2) were subjected to real- time PCR analysis. Expression of GAPDH mRNA was used as internal control. The relative
Etk level of the impact1 rat was used as the fold increase compared to left brain of normal rat. L = left brain. R = right brain. (C) Western blots were
done with antibodies to Etk and actin (loading control).
doi:10.1371/journal.pone.0039226.g001
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cells [39]. In addition, Bmx/Etk was reported to regulate Toll-like
receptor-induced IL-6 production, a cytokine closely related to
traumatic brain injury [40,41]. The possible role of Etk in post-
traumatic neural injury and in the inflammation cascadeis the
focus of this study.
Some studies have implicated GFAP, S-100b, cleaved tau, and
IL-6 as potential trauma markers [42,43,44,45]; however, other
reports have documented their limitations in clinical use [9,46,47].
An ideal biomarker should respond rapidly to the onset of disease
and be diagnostic of the condition. Furthermore, an ideal
biomarker should possess tissue specificity and be useful as a
surrogate endpoint to address therapeutic efficacy [34]. Since our
initial experiments with genetic profiling showed a moderate
increase in Etk expression levels of 1.8 to 2.5 fold in rats with
induced TBI compared to naı ¨ve rats (data not shown), we sought
to clarify the correlation between level of Etk expression and
degree of cranial trauma. In this study, we demonstrated the
potential of Etk as a neurotrauma biomarker based on its
expression correlating with the location and the degree of
traumatic brain injury.
Methods
Western Blot
Brain tissue samples were lysed in RIPA buffer. 50–100 mgo f
cell lysates were resolved on 8% to 15% SDS/PAGE gel and
transferred onto nitrocellulose membranes. Subsequently, blots
were incubated with antibodies raised against the following
proteins: anti-Bmx, anti-Stat3 (1:1000, Transduction Laborato-
ries), anti-Tec, anti-Btk, anti-Src, anti-FAK, anti- Bcl2, anti-LC3
(1:1000, Cell Signaling) and Actin (1:1000, Sigma). Donkey
peroxidase-conjugated anti-rabbit or anti-mouse antibodies
(1:1000, Amersham Pharmacia Biotech) were used and binding
was revealed by chemiluminescence (1:1000, ECL; Amersham
Pharmacia Biotech).
RT-PCR and Q-PCR
Total RNA was extracted from brain tissue by utilizing Trizol
reagent (Invitrogen). Prior to RT-PCR, 1 mg of RNA was initially
treated with DNase I (Ambion Inc., Austin, TX) to degrade
genomic DNA. Thereafter, 50 ng of treated RNA was used for
each one-step RT-PCR reaction (QIAGEN OneStep RT-PCR
Kit, Valencia, CA). Gene expression was quantified by QRT-PCR
using SYBR Green dye. All QRT-PCR reactions were performed
on a 7900 HT ABI platform (Applied Biosystems, Foster City, CA)
as previously described [48]. The sequences of primers were as
follows: GAPDH forward 59-GCACCGTCAAGGCTGAGAAC-
39 and reverse 59-ATGGTGGTGAAGACGCCA-39. GAPDH
was used to normalize the expression levels in the quantitative
analyses. The forward primer for mEtk was 5’-CACACCACCT-
CAAAGATTTCATGG-3’ and the reverse primer was 5’-
CATACTGCCCCTTCCACTTGC-3’.
Controlled-Cortical Impact
Animals were sedated prior to impact and treated according to a
Taipei Medical University Laboratory Animal protocol. Animal
studies were approved by the Institutional Animal Care and Use
Committee (IACUC) of National Defense Medical Center
Laboratory Animal Center (NDMCLAC). Adult male Sprague-
Dawley rats (weight 280–300 g) were used for this study. The
surgical procedures were modified from the Lin CM et al. (2009)
method. Under chloral hydrate (40 mg/kg, intraperitoneal, i.p.,
injection, Kanto Chemical Co., Inc.) anesthetized, SD rats were
placed in a stereotactic frame. A craniotomy of 5 mm diameter
was performed at the right parietal cortex between bregma and
Figure 2. Correlation of Etk and S100 expression with severity of impact. (A, B) Western blots revealing expression of Etk was upregulated
nearly 2-fold in rats receiving controlled cortical impact at 2.5 M/s and was further increased to 2.7-fold when impact speed was increased to 5M/s.
S100 was increased to more than 2.5 fold after impact at these speeds.
doi:10.1371/journal.pone.0039226.g002
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39226Figure 3. Triphenyltetrazolium chloride (TTC) staining of brain having received CCI. (A) Figure indicating location of site of induced
trauma. (B) Size of injured cortex was also increased proportionally to the speed of impact using triphenyltetrazolium chloride (TTC) staining.
doi:10.1371/journal.pone.0039226.g003
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controlled cortical impact (CCI) device at a velocity of 2.5 or 5 m/
sec with 1 mm depth. Body temperature was maintained at 37uC
61uC with a heating pad. Rats were sacrificed at appropriate
times for analysis, and assignments of groups were blinded to
observers. For TTC staining, animals were killed at 24 hours after
impact, the brains were removed and a series of 2-mm coronal
slices were obtained and stained in 2% triphenyltetrazolium
chloride (Sigma) in 0.9% saline, then fixed in 4% paraformalde-
hyde. The injury area, which was not stained, was measured using
a digital scanner as previously described [49].
Immunofluorescence
Twenty-four hours after TBI, rats were perfused through the
ascending aorta with 100 mL of cold normal saline followed by
100 mL of 4% paraformaldehyde (PFA) in PBS. Brains were
removed and post-fixed in the same fixative for 3 days followed by
30% sucrose for 1 week. Sections were cut at a thickness of 12
microns in a freezing microtome and stored at 220uC. For
immunostaining, tissue sections were fixed with 4% PFA for 10
minutes. After several washes in PBS, the sections were incubated
with blocking buffer containing 0.3% Triton X2100 and 4%
bovine serum albumin for 1 hour at room temperature, and were
then stained with the desired primary antibody reconstituted in
PBS, 2% goat serum at 4uC for 14–16 hours. Dilutions of the anti-
Etk (Cell Signaling), anti-neurofilament M (NF), anti-GFAP
(Transduction Laboratories) antibodies were 1:100. After three
rinses in PBS, sections were incubated with goat anti-rabbit IgG
FITC conjugate (1:100 Jackson Immunoresearch) and goat anti-
mouse IgG Rhodamine conjugate (1:100; Jackson Immunore-
search) for 1 hour at room temperature. 1mg/mL DAPI was
added to the mixture during the last 15 minutes. After several
washes in PBS, sections were mounted with Crystal Mount (Sigma)
and analyzed using a Leica microscope, a SROT RTTM CCD
camera (Diagnostic Instruments) or laser-scanning confocal
microscope (Bio-Rad, MRC-1000).
Statistics
Data are presented as mean 6 SD. Oneway ANOVA and post-
hoc Newman-Keuls tests were used for statistical comparison. A
statistically significant difference was defined at p,0.05.
Results
Impact Increased Etk Expression Compared to the
Contralateral Hemisphere
PCR product (Figure 1A), real-time PCR analysis(Figure 1B),
and Western blot analysis(Figure 1C) demonstrated that Etk
expression is increased post-impact injury when compared to the
normal cortex. Upregulated Etk expression levels were observed
Figure 4. Time course of changes in Etk and GFAP levels after controlled cortical impact. (A) Western blot of Etk and GFAP expression at
1 hour, 3 hours, 6 hours, 4 days and 7 days after impact. (B) Densitometric analysis of Etk and GFAP western blot results revealing a significant
increase at 3 hours after impact for Etk and at 4 days for GFAP. Values are expressed as mean6SD of three different experiments. *P,0.05 vs sham.
doi:10.1371/journal.pone.0039226.g004
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39226Figure 5. Immunofluorescence of Etk and GFAP at the injury site after controlled cortical impact. (A,B) Both Etk and GFAP was
detectable near the injury site, and the intensity of the immunofluorescence signal for both proteins decreases as distance increases away from injury
site. (C) Etk exhibits colocalization with neurofilament immunostaining.
doi:10.1371/journal.pone.0039226.g005
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C). The expression of Etk increased in the single impact groups by
2.36-fold (Figure 1B). Expression increased up to 7fold when
impact was performed twice. (Figure 1B, *p,0.05, One-Way
ANOVA, posthoc Newman-Keuls test).
Expression of Etk is Related to Trauma Severity as shown
by Western Blot Analysis
Since an increase in Etk level was observed upon impact with a
marked further increase observed upon second impact, the
correlation of the expression of Etk with trauma severity was
examined. Differing degrees of cortical injury were induced using
the CCI model with 2.5m/s and 5m/s speed settings. Although
S100 increased after impact, the level of increase did not vary
among the different trauma severity groups. Conversely, the
increase in the level of Etk upregulation upon impact showed
statistically significant differences between groups with varied
trauma severity (Figure 2A, 2B, *p,0.05, One-Way ANOVA,
posthoc Newman-Keuls test). Western blot analysis of Etk
correlated with the degree of injury severity revealed by TTC
staining. (Figure 3).
Etk and GFAP Increase with Respect to Time after TBI
shown by Western Blot Analysis
The expression of Etk and GFAP increased with respect to time
after injury. GFAP responded at a later stage and lasted for up to
7 days. In contrast, Etk upregulation appeared significant at
1 hour post-injury and continued to increase until 4 days after
injury (Figure 4A, 4B, *p,0.05, One-Way ANOVA, post hoc
Newman-Keuls test).
Location of Etk and GFAP with Respect to Injury Site
shown by Immunofluorescence Analysis
Etk and GFAP were localized in the impacted hemisphere
receiving mild CCI evidenced by increased fluorescence signals for
Etk and GFAP near the injury site. Levels of expression decreased
as distance from the injury site increased (Figure 5A, 5B). Etk also
exhibited colocalization with neurofilament immunostaining
(Figure 5C), suggesting the increase in Etk occurs in neurons.
These findings suggest the increase in Etk level arises from direct
injury to the neurons at the injury site.
Only Etk and Trauma/inflammation Related Markers, but
not Other Tyrosine Kinases, Increased after TBI
Western blot analyses at various times after TBI in rats revealed
increased levels of only trauma related markers and Etk. Other
tyrosine kinases and signal transduction proteins such as Tec, Btk,
Src, FAK, Stat 3, Bcl2, LC3 appeared unchanged after trauma
(Figure 6). The increase in Etk, but not other proteins, suggests
that induction of Etk is specific for traumatic brain injury.
Discussion
Etk may be an Indicator for Trauma Severity
Our results support the correlation of Etk upregulation with
trauma severity in rats. Based on the increase in Etk expression in
the injured cortex post-impact demonstrated by Western blot,
PCR, and RT-PCR, we postulate that Etk is associated with
traumatic brain injury. The correlation between the levels of Etk
expression with severity of injury was demonstrated by using
different degrees of controlled cortical impact. Furthermore, the
level of Etk increased as early as 1 hour after injury and a gradual
increase continued for 3 days or more. These increases in Etk
expression were further demonstrated by immunostaining and
correlated inversely with distance from the injury site. Taken
together, the increase in Etk observed with the increased number
of impacts, the severity of impact, and its time course after impact
as well as its inverse correlation with distance away from injury
support the possible role of Etk as a potential indicator for
traumatic neural injury severity.
Comparison to Other Markers
S100 and GFAP are two of the more accepted markers for
neural injury. Although both Etk and S100 increased after trauma,
a difference in degree of increase with respect to injury severity
was not observed for S100, yet was clearly demonstrated in the
expression of Etk. Furthermore, although both Etk and GFAP
expression demonstrated a timedependent increase after trauma,
the increase in Etk expression levelwas statistically significant at 3
hours after trauma. In contrast, the level of expression for GFAP
was not significantly different at 1 day post-trauma but increased
nearly 2- fold at 4 days post-trauma. With immunostaining of
GFAP and Etk, the difference between the two was equally
apparent at the site of injury, and both exhibited decreasing
expression at distances further away from the injury site.
Etk is Uniquely Upregulated by TBI and may be a
Potential Neurotrauma Biomarker
The upregulation of Etk is both temporally and spatially
correlated with injury. The upregulation responded more rapidly
to injury compared to GFAP.Similar post-trauma upregulation
was not observed with other tyrosine kinases of the same class or
with several other major signal transduction proteins in our study.
Thus, Etk appears to be uniquely upregulated after trauma and
may be a marker indicating trauma severity.
There are still several obstacles to be overcome before Etk can
be developed into a clinical biomarker for TBI severity. As current
detection of Etk in serum still has unresolved problems, we are
Figure 6. Western blot analysis for other proteins at various
times after impact. Other tyrosine kinases (Tec, Btk, Src, FAK)and
signal transduction proteins (Stat3, Bcl2, LC3 ) were analyzed after
impact, Etk was uniquely upregulated after injury.
doi:10.1371/journal.pone.0039226.g006
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as an alternative. In addition, while the expression of Etk is present
in other tissues such as bone marrow, and may be elevated even in
the absence of neuronal injury, its unique increase after TBI may
still provide pertinent information when used in combination with
other nerual or non-neural trauma markers.
In conclusion, unique Etk upregulation with respect to
traumatic neural injury severity suggests a possible role of Etk as
a neurotrauma marker.Its feasibility as an indicator for neuro-
trauma severity in human clinical settings warrants further clinical
investigation.
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